NS Partners Ltd Reduces Stake in Edwards Lifesciences Corporation $EW

NS Partners Ltd trimmed its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 32.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 130,801 shares of the medical research company’s stock after selling 62,432 shares during the quarter. NS Partners Ltd’s holdings in Edwards Lifesciences were worth $11,832,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Edwards Lifesciences during the 2nd quarter worth $5,318,092,000. State Street Corp grew its holdings in shares of Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after purchasing an additional 371,892 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Edwards Lifesciences by 4.8% during the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after purchasing an additional 989,533 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $1,274,082,000. Finally, Norges Bank acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $803,686,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.7%

Shares of EW stock opened at $90.86 on Tuesday. The company has a market capitalization of $52.32 billion, a P/E ratio of 52.22, a price-to-earnings-growth ratio of 2.37 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $89.64 and its two-hundred day moving average is $85.18. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on EW shares. Mizuho lifted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Piper Sandler reiterated an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Finally, Evercore reiterated an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Annette Bruls sold 2,644 shares of the business’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 5,045 shares of company stock valued at $457,749. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.